The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of

Insights

Polysorbate 80 enhances methotrexate (MTX) absorption and brain uptake. This study confirms polysorbate 80 facilitates MTX excretion and does not damage the gastrointestinal tract.

Area of Science:

  • Pharmacokinetics
  • Drug Delivery
  • Toxicology

Background:

  • Methotrexate (MTX) is a crucial chemotherapy agent.
  • Understanding factors influencing MTX absorption, distribution, and elimination is vital for optimizing treatment.
  • Polysorbate 80 is a commonly used excipient with potential pharmacokinetic effects.

Purpose of the Study:

  • To further investigate the impact of polysorbate 80 on methotrexate (MTX) pharmacokinetics.
  • To elucidate the mechanisms by which polysorbate 80 affects MTX absorption, distribution, and elimination.
  • To assess the safety of polysorbate 80 on gastrointestinal mucosa and plasma volume.

Main Methods:

  • Animal studies involving oral and intravenous administration of MTX with and without polysorbate 80.
  • Measurement of MTX concentrations in plasma, brain, urine, and feces.
  • Assessment of gastrointestinal mucosal integrity and plasma volume changes.

Main Results:

  • Polysorbate 80 significantly increased MTX absorption from the gastrointestinal tract.
  • Enhanced MTX uptake into the brain was observed, suggesting a direct effect on the blood-brain barrier.
  • Polysorbate 80 facilitated MTX excretion into bile and urine.
  • No reduction in plasma volume or damage to the gastrointestinal mucosa was detected.

Conclusions:

  • Polysorbate 80 positively modulates MTX pharmacokinetics, improving absorption and brain penetration.
  • The excipient plays a role in enhancing MTX elimination via biliary and urinary routes.
  • Polysorbate 80 appears safe for concurrent administration with MTX at tested doses, without adverse effects on GI mucosa or plasma volume.